Hikma Pharmaceuticals Plc

As of June 30, 2026, Hikma Pharmaceuticals Plc carries a market capitalization of 319.87B, placing it among publicly traded companies globally. Its enterprise value stands at 446.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hikma Pharmaceuticals Plc's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2026, Hikma Pharmaceuticals Plc has 210.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hikma Pharmaceuticals Plc maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Hikma Pharmaceuticals Plc's stock has declined approximately 4.88% over the past 52 weeks. The 50-day moving average sits at 1,611.28, while the 200-day moving average is 1,499.95.

As of June 30, 2026, Hikma Pharmaceuticals Plc holds 21.79B in cash and equivalents against 147.57B in total debt, resulting in a net debt position of 121.18B. Total book value stands at 190.25B, with working capital of 102.40B providing operational flexibility.